Cargando…

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-κB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Two exceptional responders were observed on prior clinical trials of bortezomib, both of whom had KRAS G12D-mutant NSCLC, pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drilon, Alexander, Schoenfeld, Adam J., Arbour, Kathryn C., Litvak, Anna, Ni, Ai, Montecalvo, Joseph, Yu, Helena A., Panora, Elizabeth, Ahn, Linda, Kennedy, Maureen, Haughney-Siller, Anne, Miller, Vincent, Ginsberg, Michelle, Ladanyi, Marc, Arcila, Maria, Rekhtman, Natasha, Kris, Mark G., Riely, Gregory J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549573/ https://www.ncbi.nlm.nih.gov/pubmed/30936194 http://dx.doi.org/10.1101/mcs.a003665

Ejemplares similares

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2013)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer
por: Suzawa, Ken, et al.
Publicado: (2019)

Urachal mucinous cystadenoma: An exceptional entity
por: Chaabouni, Ahmed, et al.
Publicado: (2021)

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors
por: Sato, Hiroki, et al.
Publicado: (2022)

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large cell carcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2012)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
por: Rekhtman, Natasha, et al.
Publicado: (2019)

Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
por: Charaf, Edriss, et al.
Publicado: (2009)

Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations
por: Rekhtman, Natasha, et al.
Publicado: (2017)

Comparative molecular characterization of typical and exceptional responders in glioblastoma
por: Wipfler, Kristin, et al.
Publicado: (2018)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
por: Wheler, Jennifer, et al.
Publicado: (2015)

Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS
por: Chang, Xiao Yan, et al.
Publicado: (2018)

Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices
por: Rekhtman, Natasha, et al.
Publicado: (2019)

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms
por: Lee, Yi-Ju, et al.
Publicado: (2016)

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
por: Potts, Malia B., et al.
Publicado: (2015)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts
por: Kadayifci, Abdurrahman, et al.
Publicado: (2016)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab
por: Kuang, Chaoyuan, et al.
Publicado: (2020)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM
por: Ma, Jennifer, et al.
Publicado: (2016)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component
por: Li, Xiaodong, et al.
Publicado: (2020)

Fibronectin glomerulopathy with monoclonal gammopathy responding to bortezomib plus dexamethasone: a case report
por: Li, Xiaoli, et al.
Publicado: (2022)

From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
por: Rodriguez, Julieta E., et al.
Publicado: (2023)

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
por: Arbour, Kathryn C., et al.
Publicado: (2017)

A new ankylosaurine dinosaur from the Judith River Formation of Montana, USA, based on an exceptional skeleton with soft tissue preservation
por: Arbour, Victoria M., et al.
Publicado: (2017)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials
por: van la Parra, Raquel F. D., et al.
Publicado: (2016)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
por: Kato, Shumei, et al.
Publicado: (2021)

Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition
por: Sheppard, Sarah E., et al.
Publicado: (2023)

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_90na7m3vhm3s0i9g2n110ugrsa